As of December 31, the Company was subject to lawsuits with respect to 296 injured persons alleging injuries associated with exposure of fabricators and their employees to respirable crystalline silica dust. Of these, 52 were in Israel, 122 in Australia and 122 in the United States.

In the U.S. Company was subject to an adverse jury decision in August 2024 which it is appealing and it settled another claim recently.

As of December 31, 2024, the Company has recorded a provision of $50.0 million representing its assessment of exposure that is probable and estimable with respect to pending claims in Israel, the United States and Australia.

As of December 31, 2024, the Company’s insurance receivables for silicosis-related claims totaled $32.2 million.

The Company has assessed the remaining 120 claims in the U.S. and determined that a loss is only reasonably possible or that the claims are still in an early stage. As a result, no accrual has been recorded in its financial results as of December 31, 2024.